Ibogaine in the Treatment of Chronic Hepatitis C
-
Upload
sheldon-pelletier -
Category
Health & Medicine
-
view
1.870 -
download
0
Transcript of Ibogaine in the Treatment of Chronic Hepatitis C
![Page 1: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/1.jpg)
Ibogaine in the treatment ofchronic hepatitis C
Howard S. Lotsof.President
Dora Weiner FoundationStaten Island, NY
http://www.doraweiner.org
6th National Conference on Harm Reduction
Oakland, California, November 2006
![Page 2: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/2.jpg)
Forms of ibogaine in current use
• Botanical - root bark
• Total alkaloid extract
• purified ibogaine
![Page 3: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/3.jpg)
Tabernanthe iboga shrub
![Page 4: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/4.jpg)
Roots contain ibogaine
![Page 5: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/5.jpg)
Total Alkaloid Extract
Large piece 2cm x 2cm, approx 4 grams
Estimate 15% ibogaineCourtesy Sara Glatt
![Page 6: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/6.jpg)
Ibogaine HCl
99.4% purity
![Page 7: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/7.jpg)
1973: Non A, Non B hepatitis is described
1989: HCV RNA virus identified
1990: Anti HCV effects of ibogaine
reported
2005: Patent application for ibogaine to
treat chronic HCV
Hepatitis C (HCV)timeline
![Page 8: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/8.jpg)
Most common viral infection in the
United States
New infections per year 1990 - 242,000New infections per year 2001 - 25,000New infections per year 2004 - 25,000Greater than 75% of IVDUs test
positive
HCV infection
![Page 9: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/9.jpg)
1. The discovery of ibogaine’s use in treating both chemical dependence and HCV was by ibogaine activist advocates who were themselves treated or self-treated with ibogaine.
2. Scientific research followed patent development in the treatment of chemical dependence and it is hoped the same will be true for ibogaine related HCV research.
Science follows patent development
![Page 10: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/10.jpg)
1. Rapid method for interrupting the narcotic addiction syndrome, US 4,499,096 (1985)
2. Rapid method for interrupting the cocaine and amphetamine abuse syndrome US 4,587,243 (1986)
3. Rapid method for attenuating the alcohol dependency syndrome, US 4,957,523 (1989)
4. Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US 5,026,697 (1991)
5. Rapid method for interrupting or attenuating poly-drug dependency syndromes, US 5, 124,994 (1992)
Ibogaine Patents
![Page 11: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/11.jpg)
1. Broad ranging claims of ibogaine to treat multiple forms of chemical dependence doubted
2. Over time, all claims for treating chemical dependence have been confirmed by research
a) Opioids,
b) stimulants,
c) Alcohol
d) nicotine
Research follows skepticism
![Page 12: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/12.jpg)
Opioids
![Page 13: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/13.jpg)
Cocaine
![Page 14: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/14.jpg)
Alcohol
![Page 15: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/15.jpg)
Nicotine
![Page 16: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/16.jpg)
• International Coalition for Addict Self-Help (ICASH) 1989
• Dutch Addict Self-Help (DASH) 1990
• Ibogaine Underground 2004
Ibogaine activist organizations play
role in ibogaine HCV research
![Page 17: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/17.jpg)
HCV patent application
![Page 18: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/18.jpg)
Example 1 Report
A thirty-three year old male diagnosed with HCV and using 1/4 gram of heroin a day was administered 25 mg/kg ibogaine HCl. Following administration of ibogaine heroin use ceased along with swelling of the liver and pain in the area of the liver.
![Page 19: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/19.jpg)
Example 2 Liver enzyme values reduced
by 14 mg/kg ibogaine
Enzyme Pre Post
ALT 410 50
AST 201 25
GGT 155 33
![Page 20: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/20.jpg)
Example 3
![Page 21: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/21.jpg)
Example. 4 A forty-two year old female testing positive for HCV RNA type 3. RNA IU/ml was 12,600,000. Subject was administered a total of 27 mg/kg ibogaine HCl in the following regimen:
6 x 2 mg/kg1 x 12 mg/kg1 x 3 mg/kg
HCV RNA IU/ml was reduced to 50,100. Prior to ibogaine treatment patient’s urine was dark and stool light. Post treatment color of urine and stool returned to normal.
![Page 22: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/22.jpg)
Encouraging results
1. Repetitive low dosing with ibogaine provided continuous depression of viral load.
2. Genotype 3 appears highly responsive in keeping with results of interferon riboviron therapy.
3. Continued reduction in viral load after stopping of ibogaine therapy observed.
4. Less toxic than current HCV therapies.
![Page 23: Ibogaine in the Treatment of Chronic Hepatitis C](https://reader030.fdocuments.in/reader030/viewer/2022013003/558501a3d8b42ab8128b4f5e/html5/thumbnails/23.jpg)
Future development
1. Interest of pharmaceutical companies with experience in development of HCV drugs.
2. Preclinical confirmation of efficacy if possible.
3. Phase I/II clinical studies to confirm findings and establish preferred dose regimen.